Chronic Hepatitis B
Conditions
Interventions
Bacteria Transplantation Group:Bacteria Transplantation
Control Group:Oral Antiviral Therapy
Sponsors
Zhongshan Hospital Affiliated to Xiamen University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 18~70 years old with HBeAg positive CHB; Underwent more than 3 years of antiviral therapy whereas HBeAg remains positive; Ongoing ETV or TDF based antiviral therapy; HBV DNA levels <10, 000 IU/mL; Alanine aminotransferase (ALT) levels <80 U/L; Subjects who have using interferon or pegylated interferon with the last dose at least 24 weeks before screening
Exclusion criteria
Exclusion criteria: Alcoholism; Genetic or metabolic liver diseases, such as Wilsons disease, hemachromatosis, etc. Co-infection of HAV, HCV, HEV, EBV and CMV; Concurrent malignant tumors; Autoimmune liver diseases; Liver cirrhosis with decompensated liver function; Pregnant or lactating women; Concurrent conditions that is contraindicated for endoscopy; A ceased previous history in the past 26 weeks of using interferon or pegylated interferon
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HBeAg Clearance; | — |
Secondary
| Measure | Time frame |
|---|---|
| Decline of HBeAg Titer;The structural and quantity alterations of intestinal flora pre- and after fecal transplantation; | — |
Countries
China
Contacts
Public ContactJin-Shui Pan
Zhongshan Hospital Affiliated to Xiamen University
Outcome results
None listed